Table 1. Description of the cohort (n=33).
| Demographic and clinical characteristics | ||
|---|---|---|
| Female sex, n (%) | 14 (42%) | |
| Age (median years, IQR) | 36 (31 - 42) | |
| Baseline BMI (median kg/m2, IQR) | 16.7 (15.4 - 17.6) | |
| Week 12 BMI (median kg/m2, IQR) | 17.6 (16.5 – 19.0)a | |
| Baseline CD4+ count (median cells/μL, IQR) | 224 (151 - 273) | |
| Week 12 CD4+ count (median cells/μL, IQR) | 349 (275 - 426)a | |
| Median serum, urine, and cardiovascular values pre-treatment and after 12 weeks of antiretroviral therapy, median (IQR) | ||
| Variable | Recruitment | Week 12 of ART |
| C-reactive protein (mg/l) | 18.3 (4.5-64.8) | 6.4 (3.8-19.7)a |
| TNF-α receptor 1 (ng/ml) | 1.3 (0.8 – 2.4) | 1.0 (0.6 – 1.3)a |
| Soluble CD163 (ng/ml) | 684 (511 - 1022) | 531 (376 - 1040) |
| Soluble CD14 (μg/ml) | 2.4 (2.1-2.7) | 2.5 (2.0-3.1) |
| Isoprostane-to-creatinine ratio | 0.02 (0.01-0.05) | 0.09 (0.05-0.24)a |
| Augmentation Index | 11.9 (1.0-30.0) | 19.0 (0.1-25.9) |
| Reactive Hyperemia Index | 0.6 (0.3-0.8) | 0.6 (0.4-0.7) |
| QTc (ms) | 434 (421-447) | 431 (417-446) |
| RMSSD (ms) | 26.4 (17.5-41.3) | 37.2 (19.2-71.6)a |
| Triangular Index | 6.8 (5.9-10.6) | 9.6 (6.1-14.5) |
| Low frequency variations (ms2) | 130.2 (85.0-151.9) | 112.9 (76.1-151.6) |
| High frequency variations (ms2) | 214.7 (154.7-260.8) | 232.6 (169.7-327.1) |
| Power Ratio | 0.6 (0.4-0.9) | 0.4 (0.3-0.9) |
| Systolic blood pressure (mm Hg) | 100 (93-110) | 110 (100-120)a |
| Diastolic blood pressure (mm Hg) | 60 (60-70) | 70 (60-70) |
| Heart rate (bpm) | 78 (71-89) | 68 (63-82) |
Abbreviation: BMI, body mass index; QTC, corrected QT interval; RMSSD, root mean square of the successive differences; TNF-α, tumor necrosis factor-α.
Reactive hyperemia index is natural log transformed
a
p<0.05 for change at 12 weeks